This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
RVL Pharmaceuticals PLC (RVLP) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
RVL Pharmaceuticals PLC (RVLP) delivered earnings and revenue surprises of 10.34% and 7.83%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: USANA Health Sciences (USNA) Q4 Earnings Expected to Decline
by Zacks Equity Research
USANA Health (USNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ChemoCentryx's (CCXI) Stock Increases on Tavneos' FDA Nod
by Zacks Equity Research
ChemoCentryx's (CCXI) Tavneos gives a significant boost to the company, following its FDA approval in ANCA-associated vasculitis. The drug is also being evaluated in other indications.
USANA Health Sciences (USNA) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
USANA Health (USNA) delivered earnings and revenue surprises of 4.62% and 2.10%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate USANA Health Sciences (USNA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
USANA Health (USNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for September 29th
by Zacks Equity Research
AFMD, FSLR, MU, BCE, and USNA have been added to the Zacks Rank #5 (Strong Sell) List on September 29, 2021.
Catalyst (CPRX) Q2 Earnings Top Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Catalyst's (CPRX) earnings and revenues beat estimates in the second quarter of 2021. Shares inch up in after-hours trading.
USANA Health Sciences (USNA) Beats Q2 Earnings Estimates
by Zacks Equity Research
USANA Health (USNA) delivered earnings and revenue surprises of 5.06% and -0.99%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
USANA Health Sciences (USNA) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
USANA Health (USNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
USANA Health Sciences (USNA) Q1 Earnings Lag Estimates
by Zacks Equity Research
USANA Health (USNA) delivered earnings and revenue surprises of -7.64% and 2.52%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Apply DuPont Strategy to Pick 5 Top-Ranked Healthy Stocks
by Sanghamitra Saha
Why you should depend on the DuPont technique to pick solid profit-generating stocks.
Jazz's (JAZZ) Vyxeos Gets FDA Nod for Pediatric Leukemia
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) gets FDA approval for label expansion of its cancer drug, Vyxeos, in pediatric patients with newly-diagnosed therapy-related acute myeloid leukemia.
Zacks.com featured highlights include: Medifast, 1800 FLOWERS.COM, USANA Health Sciences, UFP Industries and AllianceBernstein
by Zacks Equity Research
Zacks.com featured highlights include: Medifast, 1800 FLOWERS.COM, USANA Health Sciences, UFP Industries and AllianceBernstein
5 Best Stocks to Buy After Analyzing ROE the DuPont Way
by Sanghamitra Saha
Delving into the basic ROE, with the help of DuPont analysis, before shortlisting stocks could lead to even better returns.
USNA vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
USNA vs. ZTS: Which Stock Is the Better Value Option?
USANA Health (USNA) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
USANA Health (USNA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Explore 5 Top-Ranked Stocks Using the DuPont Analysis
by Sanghamitra Saha
Have more faith in DuPont analysis than simple ROE calculation? Bet on these five stocks.
USNA or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
USNA vs. ZTS: Which Stock Is the Better Value Option?
Esperion (ESPR) Q4 Earnings Miss, Coronavirus Woes Continue
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports dismal fourth-quarter results as it misses estimates for earnings and sales. Sales were hurt due to COVID-19.
Jazz Pharma (JAZZ) Q4 Earnings Miss, 2021 Sales View Dull
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) reports mixed fourth-quarter 2020 results as earnings miss estimates while sales beat the same. Shares down.
5 Low Price-to-Book Stocks for Value Investors
by Kinjel Shah
P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.
Zacks Industry Outlook Highlights: Radius Health, USANA Health Sciences, Organogenesis Holdings, Turning Point Therapeutics and Oncternal Therapeutics
by Zacks Equity Research
Zacks Industry Outlook Highlights: Radius Health, USANA Health Sciences, Organogenesis Holdings, Turning Point Therapeutics and Oncternal Therapeutics
Moving Average Crossover Alert: USANA Health Sciences (USNA)
by Zacks Equity Research
USANA Health Sciences (USNA) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
5 Small Drug Stocks to Buy Amid Lingering COVID-Led Uncertainty
by Kinjel Shah
Some residual impact of the coronavirus pandemic is expected on the Medical-Drugs industry in 2021. However, with demand trends expected to improve, USNA, RDUS, ONCT, ORGO and TPTX may prove to be good additions to one's portfolio.
USNA vs. CTLT: Which Stock Is the Better Value Option?
by Zacks Equity Research
USNA vs. CTLT: Which Stock Is the Better Value Option?